ONCY - Oncolytics up 54% in last three trading sessions
2023-06-23 12:53:42 ET
- Oncolytics Biotech ( NASDAQ: ONCY ) is up an impressive 54% since the market close on June 20.
- In early afternoon trading Friday, the stock is up 17% .
- The reason for the jump is that its oncologic pelareorep has been selected for inclusion in a phase 3 trial of pancreatic cancer treatments.
- Pelareorep will be tested in the Precision Promise study in combination with a checkpoint inhibitor and gemcitabine and nab-paclitaxel.
- If successful, the combination could be approved as a first-line metastatic pancreatic ductal adenocarcinoma treatment.
- Seeking Alpha's Quant Rating views Oncolytics ( ONCY ) as a hold.
For further details see:
Oncolytics up 54% in last three trading sessions